» Articles » PMID: 25344603

Interaction with Both Domain I and III of Albumin is Required for Optimal PH-dependent Binding to the Neonatal Fc Receptor (FcRn)

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2014 Oct 26
PMID 25344603
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Albumin is an abundant blood protein that acts as a transporter of a plethora of small molecules like fatty acids, hormones, toxins, and drugs. In addition, it has an unusual long serum half-life in humans of nearly 3 weeks, which is attributed to its interaction with the neonatal Fc receptor (FcRn). FcRn protects albumin from intracellular degradation via a pH-dependent cellular recycling mechanism. To understand how FcRn impacts the role of albumin as a distributor, it is of importance to unravel the structural mechanism that determines pH-dependent binding. Here, we show that although the C-terminal domain III (DIII) of human serum albumin (HSA) contains the principal binding site, the N-terminal domain I (DI) is important for optimal FcRn binding. Specifically, structural inspection of human FcRn (hFcRn) in complex with HSA revealed that two exposed loops of DI were in proximity with the receptor. To investigate to what extent these contacts affected hFcRn binding, we targeted selected amino acid residues of the loops by mutagenesis. Screening by in vitro interaction assays revealed that several of the engineered HSA variants showed decreased binding to hFcRn, which was also the case for two missense variants with mutations within these loops. In addition, four of the variants showed improved binding. Our findings demonstrate that both DI and DIII are required for optimal binding to FcRn, which has implications for our understanding of the FcRn-albumin relationship and how albumin acts as a distributor. Such knowledge may inspire development of novel HSA-based diagnostics and therapeutics.

Citing Articles

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Mester S, Chan C, Lustig M, Foss S, Jansen J, Leangen Herigstad M PNAS Nexus. 2025; 4(2):pgaf042.

PMID: 40041621 PMC: 11878800. DOI: 10.1093/pnasnexus/pgaf042.


Computational Study of Molecular Mechanism for the Involvement of Human Serum Albumin in the Renin-Angiotensin-Aldosterone System.

Belinskaia D, Shestakova N, Samodurova K, Goncharov N Int J Mol Sci. 2024; 25(19).

PMID: 39408590 PMC: 11476573. DOI: 10.3390/ijms251910260.


The blistering warfare agent O-mustard (agent T) generates protein-adducts with human serum albumin useful for biomedical verification of exposure and forms intramolecular cross-links.

Blum M, Schmeisser W, Dentzel M, Thiermann H, John H Anal Bioanal Chem. 2024; 416(26):5791-5804.

PMID: 39215775 PMC: 11493803. DOI: 10.1007/s00216-024-05501-8.


A Silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics.

Gjolberg T, Lode H, Melo G, Mester S, Probst C, Sivertsen M Front Ophthalmol (Lausanne). 2024; 2:882013.

PMID: 38983507 PMC: 11182194. DOI: 10.3389/fopht.2022.882013.


Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.

Lombardi S, Aaen K, Nilsen J, Ferrarese M, Gjolberg T, Bernardi F Br J Haematol. 2021; 194(2):453-462.

PMID: 34109608 PMC: 8362221. DOI: 10.1111/bjh.17559.


References
1.
Andersen J, Dalhus B, Cameron J, Daba M, Plumridge A, Evans L . Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun. 2012; 3:610. PMC: 3272563. DOI: 10.1038/ncomms1607. View

2.
Elsadek B, Kratz F . Impact of albumin on drug delivery--new applications on the horizon. J Control Release. 2011; 157(1):4-28. DOI: 10.1016/j.jconrel.2011.09.069. View

3.
Andersen J, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I . Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem. 2013; 288(33):24277-85. PMC: 3745371. DOI: 10.1074/jbc.M113.463000. View

4.
Kragh-Hansen U, Minchiotti L, Galliano M, Peters Jr T . Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta. 2013; 1830(12):5405-17. DOI: 10.1016/j.bbagen.2013.03.026. View

5.
Sleep D, Cameron J, Evans L . Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013; 1830(12):5526-34. DOI: 10.1016/j.bbagen.2013.04.023. View